Please assess the completion status of the following clinical trial:

Trial Title: Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pakistani muslim male / female, type 2 diabetic patient having age from 18 years to 75 years~* Patient who give informed consent voluntarily~* BMI ≤45 kg/m2~* Glycosylated hemoglobin of 7 - ≤10%~Exclusion Criteria:~* Patients who are on empagliflozin treatment~* Indication of liver disease, defined by serum levels of either alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase above 3 times upper limit to normal~* Estimated glomerular filtration rate (eGFR) \<45 mL /min /1.73m2~* History of recurrent urinary tract infection (UTI) and/or past 3 months' history of UTI and its treatment~* Patients with positive urine culture for UTI at the time of screening~* Patients who have been admitted to the hospital in the past 3 months for diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state~* Patients with past 3 months' history of fungal infection and its treatment~* History of blood dyscrasias or any disorders causing haemolysis or unstable red blood cell~* History of benign prostate hyperplasia~* Any acute coronary syndrome, stroke and/or transient ischemic attack (TIA) in the previous 3 months~* Any contraindication for patients to Biguanides, Sulfonylureas, DPP-IV inhibitors, SGLT-2 Inhibitors~* Treatment with anti-obesity drugs or any other treatment leading to unstable body weight~* Patients with past 6 weeks treatment history with systemic steroids or thyroid hormones or any other uncontrolled endocrine disorder except T2DM~* Pre-menopausal women who are nursing or pregnant or are of childbearing potential and not practicing an acceptable method of birth control~* Any other clinical condition that would jeopardize patients safety while participating in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Empagliflozin (Type: EXPERIMENTAL): None
- Usual Care Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).